Patents by Inventor Toshikazu Ushijima
Toshikazu Ushijima has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11214838Abstract: The present invention provides a factor capable of predicting an effect of a medicinal therapy on a cancer such as HER2 positive cancer. More specifically, the present invention provides a method of predicting the effect of the medicinal therapy on the cancer, comprising: (1) analyzing a methylation level of a cytosine residue in one or more CpG sites present within a nucleotide sequence in a promotor region, an untranslated region or a translated region of HSD17B4 gene in a sample taken from a human subject; and (2) predicting the effect of the medicinal therapy on the cancer based on the analyzed methylation level.Type: GrantFiled: March 15, 2017Date of Patent: January 4, 2022Assignees: NATIONAL CANCER CENTER, H.U. Group Research Institute G.K.Inventors: Hirofumi Mukai, Toshikazu Ushijima, Satoshi Yamashita
-
Patent number: 11173174Abstract: [Problem] To provide, in place of injected agents (such as Vidaza® and Dacogen®) clinically used as therapeutic drugs for high-risk myelodysplastic syndromes, a medicine as a therapeutic drug or a prophylactic drug for various advanced solid tumors, said medicine having high stability with respect to cytidine deaminase which is a hydrolytic metabolic enzyme, being absorbed into the body even by oral administration, and having an effect of being integrated into a nucleic acid biosynthetic route and inhibiting DNA methyltransferases, i.e., DNMTs. [Solution] The aforementioned problem is solved by a novel compound represented by formula (I). (In the formula, R is a hydroxyl group or a hydrogen atom, and R1 and R2 are each a benzyl group that may have a substituent.Type: GrantFiled: April 24, 2018Date of Patent: November 16, 2021Assignee: Ohara Pharmaceutical Co., Ltd.Inventors: Sako Magoichi, Toshikazu Ushijima, Naoko Hattori
-
Publication number: 20210285057Abstract: An indicator may have improved accuracy for predicting an effect of a medicinal therapy on breast cancer. The method may estimate a breast cancer cell existence ratio and other methods, the method including: (1) analyzing methylation level of (1a) a cytosine residue in a CG portion of nucleotides at positions 1,000 to 1,001 in a nucleotide sequence of SEQ ID NO: 1, (1b) a cytosine residue in a CG portion of nucleotides at positions 1,000 to 1,001 in a nucleotide sequence of SEQ ID NO: 2, (1c) a cytosine residue in a CG portion of nucleotides at positions 1,001 to 1,002 in a nucleotide sequence of SEQ ID NO: 3, or (1d) a combination of the cytosine residues, in a sample derived from a human subject; and (2) estimating the breast cancer cell existence ratio in the sample, based on the methylation level analyzed at (1).Type: ApplicationFiled: September 11, 2019Publication date: September 16, 2021Applicants: NATIONAL CANCER CENTER, H.U. Group Research Institute G.K.Inventors: Hiroki ISHIHARA, Toshikazu USHIJIMA
-
Publication number: 20190169701Abstract: The present invention provides a factor capable of predicting an effect of a medicinal therapy on a cancer such as HER2 positive cancer. More specifically, the present invention provides a method of predicting the effect of the medicinal therapy on the cancer, comprising: (1) analyzing a methylation level of a cytosine residue in one or more CpG sites present within a nucleotide sequence in a promotor region, an untranslated region or a translated region of HSD17B4 gene in a sample taken from a human subject; and (2) predicting the effect of the medicinal therapy on the cancer based on the analyzed methylation level.Type: ApplicationFiled: March 15, 2017Publication date: June 6, 2019Applicants: NATIONAL CANCER CENTER, Miraca Research Institute G.K.Inventors: Hirofumi MUKAI, Toshikazu USHIJIMA, Satoshi YAMASHITA
-
Publication number: 20170101670Abstract: Disclosed is a method for detecting a rare mutation. The method comprises: preparing a sample comprising not more than 1,000 copies of template DNA; amplifying the template DNA to prepare a library, and analyzing a nucleotide sequence of the library; calculating a ratio of variants in a base at a predetermined position, from the analysis result; comparing the calculated ratio of variants with a predetermined cut-off value; and determining that the sample has a rare mutation in the base at the predetermined position when the calculated ratio of variants is not less than the predetermined cut-off value.Type: ApplicationFiled: October 6, 2016Publication date: April 13, 2017Applicants: NATIONAL CANCER CENTER, SYSMEX CORPORATIONInventors: Toshikazu USHIJIMA, Satoshi YAMASHITA
-
Patent number: 8980559Abstract: The present invention relates to a method for assessing a cancerous state of a mammal-derived specimen, which comprises: (1) a first step of measuring a methylation frequency of Neurofilament3 gene contained in a mammal-derived specimen or an index value having the correlation therewith, and (2) a second step of determining a cancerous state of the specimen based on a difference obtained by comparing the measured methylation frequency or the index value having the correlation therewith, with a control; and the like.Type: GrantFiled: September 15, 2004Date of Patent: March 17, 2015Assignees: Sumitomo Chemical Company, Limited, Japan as Represented by President of National Cancer CenterInventors: Toshikazu Ushijima, Atsushi Hagihara
-
Patent number: 7763422Abstract: The present invention relates to a method for assessing a cancerous state of a mammal-derived specimen, which comprises: (1) a first step of measuring a methylation frequency of Fibrillin2 gene contained in a mammal-derived specimen or an index value having the correlation therewith, and (2) a second step of determining a cancerous state of the specimen based on a difference obtained by comparing the measured methylation frequency or the index value having the correlation therewith, with a control; and the like.Type: GrantFiled: September 15, 2004Date of Patent: July 27, 2010Assignees: Sumitomo Chemical Company, Limited, Japan as Represented by President of National Cancer CenterInventors: Toshikazu Ushijima, Atsushi Hagihara
-
Publication number: 20070244030Abstract: The present invention relates to a method for assessing a cancerous state of a mammal-derived specimen, which comprises: (1) a first step of measuring a methylation frequency of Neurofilament3 gene contained in a mammal-derived specimen or an index value having the correlation therewith, and (2) a second step of determining a cancerous state of the specimen based on a difference obtained by comparing the measured methylation frequency or the index value having the correlation therewith, with a control; and the like.Type: ApplicationFiled: September 15, 2004Publication date: October 18, 2007Applicants: SUMITOMO CHEMICAL COMPANY, LIMITED, JAPAN AS REPRESENTED BY PRESIDENT OF NATIONAL CANCInventors: Toshikazu Ushijima, Atsushi Hagihara
-
Publication number: 20070135366Abstract: The present invention relates to a method for assessing a cancerous state of a mammal-derived specimen, which comprises: (1) a first step of measuring a methylation frequency of FiLbrillin2 gene contained in a mammal-derived specimen or an index value having the correlation therewith, and (2) a second step of determining a cancerous state of the specimen based on a difference obtained by comparing the measured meithylation frequency or the index value having the correlation therewith, with a control; and the like.Type: ApplicationFiled: September 15, 2004Publication date: June 14, 2007Applicants: SUMITOMO CHEMICAL COMPANY, LIMITED., JAPAN AS REPRESENTED BY PRESICENT OF NATIONAL CANCInventors: Toshikazu Ushijima, Atsushi Hagihara
-
Publication number: 20050064412Abstract: The present invention relates to a method for assessing a cancerous state of a mammal-derived specimen, which comprises: (1) a first step of measuring a methylation frequency of Heparan sulfate D-glucosaminyl 3-0-sulfotransferase gene contained in a mammal-derived specimen or an index value having the correlation therewith, and (2) a second step of determining a cancerous state of the specimen based on a difference obtained by comparing the measured methylation frequency or the index value having the correlation therewith, with a control; and the like.Type: ApplicationFiled: August 9, 2002Publication date: March 24, 2005Inventors: Toshikazu Ushijima, Kazuaki Miyamoto